[go: up one dir, main page]

RU97101084A - STRAIN STREPTOCOCCUS EQUI, MICROBIOLOGICALLY CLEAN CULTURE, LIVING VACCINE AND METHOD FOR PRODUCING IT - Google Patents

STRAIN STREPTOCOCCUS EQUI, MICROBIOLOGICALLY CLEAN CULTURE, LIVING VACCINE AND METHOD FOR PRODUCING IT

Info

Publication number
RU97101084A
RU97101084A RU97101084/13A RU97101084A RU97101084A RU 97101084 A RU97101084 A RU 97101084A RU 97101084/13 A RU97101084/13 A RU 97101084/13A RU 97101084 A RU97101084 A RU 97101084A RU 97101084 A RU97101084 A RU 97101084A
Authority
RU
Russia
Prior art keywords
virus
vaccine
strain
streptococcus equi
vaccine according
Prior art date
Application number
RU97101084/13A
Other languages
Russian (ru)
Other versions
RU2194752C2 (en
Inventor
Мари Хартфорд Орла
Джеймс Фостер Тимоти
Арнодус Кристиаан Якобс Антониус
Original Assignee
Дзе Провост Феллоус энд Сколарс оф дзе Колледж оф Дзе Холи Андивайдед Тринити оф Квин Элизабет Неар Дублин
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дзе Провост Феллоус энд Сколарс оф дзе Колледж оф Дзе Холи Андивайдед Тринити оф Квин Элизабет Неар Дублин filed Critical Дзе Провост Феллоус энд Сколарс оф дзе Колледж оф Дзе Холи Андивайдед Тринити оф Квин Элизабет Неар Дублин
Publication of RU97101084A publication Critical patent/RU97101084A/en
Application granted granted Critical
Publication of RU2194752C2 publication Critical patent/RU2194752C2/en

Links

Claims (10)

1. Штамм Streptococcus equi ТW 928, депонированный под номером СВS 813.95 (Centraalbureau voor Schimmelcultures at Baam, The Netherlands).1. The strain Streptococcus equi TW 928, deposited under the number CBS 813.95 (Centraalbureau voor Schimmelcultures at Baam, The Netherlands). 2. Микробиологическая чистая культура, включающая бактерии, отличающаяся тем, что культура включает штамм Streptococcus equi ТW 928 по п. 1. 2. Microbiological pure culture, including bacteria, characterized in that the culture includes a strain of Streptococcus equi TW 928 according to claim 1. 3. Живая вакцина для борьбы с Streptococcus инфекцией лошадей, отличающаяся тем, что указанная вакцина включает штамм Streptococcus equi ТW 928 по п. 1 и фармацевтически приемлемый носитель. 3. A live vaccine for controlling Streptococcus infection in horses, wherein said vaccine comprises a Streptococcus equi strain TW 928 according to claim 1 and a pharmaceutically acceptable carrier. 4. Вакцина по п. 3, отличающаяся тем, что она пригодна для внутриназального применения. 4. The vaccine according to claim 3, characterized in that it is suitable for intranasal use. 5. Вакцина по п. 3 или 4, отличающаяся тем, что она находится в высушенной вымораживанием форме. 5. The vaccine according to claim 3 or 4, characterized in that it is in a freeze-dried form. 6. Вакцина по любому из пп. 3-5, отличающаяся тем, что она дополнительно включает другой ослабленный патоген или антигенное вещество из другого патогена. 6. The vaccine according to any one of paragraphs. 3-5, characterized in that it further includes another attenuated pathogen or antigenic substance from another pathogen. 7. Вакцина по п. 6, отличающаяся тем, что указанный дополнительный патоген выбран из группы, состоящей из возбудителя Potomas лихорадки, Rhodococcus equi, Clostridium tetanii, Mycobacterium pseudomallei, вируса везикулярного стоматита, вируса болезни Borna, вируса лошадиного гриппа, вируса болезни Африканских лошадей, вируса лошадиного артрита, вируса лошадиного герпеса 1-4, вируса инфекционной анемии, вируса энцефаломиелита лошадей и вируса японского В энцефалита. 7. The vaccine according to claim 6, characterized in that the additional pathogen is selected from the group consisting of the causative agent Potomas fever, Rhodococcus equi, Clostridium tetanii, Mycobacterium pseudomallei, vesicular stomatitis virus, Borna disease virus, equine influenza virus, African horses disease virus , equine arthritis virus, equine herpes virus 1-4, infectious anemia virus, equine encephalomyelitis virus and Japanese B encephalitis virus. 8. Вакцина по любому из пп. 3-7, отличающаяся тем, что она включает адъюванты. 8. The vaccine according to any one of paragraphs. 3-7, characterized in that it includes adjuvants. 9. Способ получения вакцины по пп. 3-8, отличающийся тем, что способ включает смешение штамма бактерий Streptococcus equi TW 928 и фармацевтически приемлемого носителя. 9. A method of obtaining a vaccine according to claims. 3-8, characterized in that the method comprises mixing a strain of bacteria Streptococcus equi TW 928 and a pharmaceutically acceptable carrier. 10. Штамм Streptococcus equi TW 928, СВS 813.95 по п. 1 полезный для приготовления вакцины для борьбы с Streptococcus инфекцией у лошадей. 10. The strain Streptococcus equi TW 928, CBS 813.95 according to claim 1 is useful for preparing a vaccine for combating Streptococcus infection in horses.
RU97101084/13A 1996-01-25 1997-01-24 Strain and culture of strain streptococcus equi tw 928 for horse vaccination RU2194752C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP96200171.5 1996-01-25
EP96200171 1996-01-25

Publications (2)

Publication Number Publication Date
RU97101084A true RU97101084A (en) 1999-05-10
RU2194752C2 RU2194752C2 (en) 2002-12-20

Family

ID=8223610

Family Applications (1)

Application Number Title Priority Date Filing Date
RU97101084/13A RU2194752C2 (en) 1996-01-25 1997-01-24 Strain and culture of strain streptococcus equi tw 928 for horse vaccination

Country Status (16)

Country Link
US (1) US5895654A (en)
EP (1) EP0786518B1 (en)
JP (1) JP3911058B2 (en)
AT (1) ATE219511T1 (en)
AU (1) AU703942B2 (en)
BR (1) BRPI9700768B8 (en)
CA (1) CA2195935C (en)
CZ (1) CZ289530B6 (en)
DE (1) DE69713408T2 (en)
DK (1) DK0786518T3 (en)
ES (1) ES2179261T3 (en)
NZ (1) NZ314091A (en)
PL (1) PL187163B1 (en)
PT (1) PT786518E (en)
RU (1) RU2194752C2 (en)
ZA (1) ZA97452B (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2243730C (en) * 1997-07-29 2009-12-22 Akzo Nobel N.V. Streptococcus equi vaccine
US6682745B1 (en) 1998-07-28 2004-01-27 Christiaan Antonius Arnoldus Jacobs Use of bacterium for manufacture of a vaccine
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20080050367A1 (en) * 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
JP2002511385A (en) * 1997-12-03 2002-04-16 ニューララブ リミテッド Method for suppressing β-amyloid-related changes in Alzheimer's disease
FR2775601B1 (en) 1998-03-03 2001-09-21 Merial Sas RECOMBINANT LIVING VACCINES AND ADJUVANTS
DE60007668T2 (en) * 1999-01-26 2004-12-02 Akzo Nobel N.V. Use of live attenuated bacteria to produce a submucosal vaccine
FR2796397B1 (en) * 1999-07-16 2006-09-01 Merial Sas FELIN CALICIVIRUS GENES AND VACCINES, INCLUDING RECOMBINANT VACCINES
US6541458B1 (en) 1999-07-16 2003-04-01 Merial Feline calicivirus genes and vaccines in particular recombinant vaccines
US8889112B2 (en) * 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
US20020082288A1 (en) * 1999-09-16 2002-06-27 Gerald Horn Ophthalmic formulations comprising an imidazoline
US6420407B1 (en) 1999-09-16 2002-07-16 Gerald Horn Ophthalmic formulation which modulates dilation
US6730065B1 (en) * 2000-09-15 2004-05-04 Ocularis Pharma, Inc. Night vision composition
US20060211753A1 (en) * 2000-11-03 2006-09-21 Ocularis Pharma, Inc. Method and composition which reduces stimulation of muscles which dilate the eye
GB2370770B (en) * 2001-01-03 2005-06-01 Simon Connolly Uses of Streptococcus Vaccines
TW200635607A (en) 2004-12-15 2006-10-16 Elan Pharm Inc Humanized Aβ antibodies for use in improving cognition
US8784810B2 (en) * 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
PT2182983E (en) * 2007-07-27 2014-09-01 Janssen Alzheimer Immunotherap Treatment of amyloidogenic diseases with humanised anti-abeta antibodies
JO3076B1 (en) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap Immunotherapy regimes dependent on apoe status
GB0801326D0 (en) 2008-01-24 2008-03-05 Animal Health Trust Vaccines
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
GB201209014D0 (en) * 2012-05-22 2012-07-04 Moredun Res Inst Vaccine
US9089560B2 (en) 2013-02-01 2015-07-28 Ocularis Pharma, Llc Methods and compositions for daily ophthalmic administration of phentolamine to improve visual performance
CA2899339C (en) 2013-02-01 2021-07-06 Ocularis Pharma, Llc Aqueous ophthalmic solutions of phentolamine and medical uses thereof
RU2016114713A (en) 2013-10-17 2017-11-20 Зоэтис Сервисиз Ллс METHODS AND COMPOSITIONS FOR TREATMENT OF S. EQUI INFECTIONS
EP2949340A1 (en) * 2014-05-30 2015-12-02 IDT Biologika GmbH Vaccine composition against Streptococcus suis infection
GB2564481B (en) * 2017-07-14 2019-10-23 4D Pharma Leon S L U Process
AU2019360953A1 (en) 2018-10-15 2021-05-13 Ocuphire Pharma, Inc. Methods and compositions for treatment of glaucoma and related conditions
EP3870170A4 (en) 2018-10-26 2022-07-20 Ocuphire Pharma, Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF PRESBYOPIA, MYDRIASIS AND OTHER EYE DISEASES
CN115368310A (en) 2021-05-18 2022-11-22 奥库菲尔医药公司 Method for synthesizing phentolamine mesylate

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4110433A (en) * 1976-04-23 1978-08-29 Philips Roxane, Inc. Equine rhinopneumonitis virus
SE8205892D0 (en) 1982-10-18 1982-10-18 Bror Morein IMMUNOGENT MEMBRANE PROTEIN COMPLEX, SET FOR PREPARATION AND USE THEREOF
US4582798A (en) * 1984-11-23 1986-04-15 Miles Laboratories, Inc. Preparation and use of enzyme-detergent extracted Streptococcus equi vaccine
AR241545A1 (en) * 1985-07-12 1992-08-31 Cornell Res Foundation Inc The protection of equines against streptococcus equi
US4788059A (en) * 1985-07-15 1988-11-29 Coopers Animal Health, Inc. Equine strangles vaccine and the method of preparing and using the same
US5294441A (en) * 1987-06-04 1994-03-15 Washington University Avirulent microbes and uses therefor: salmonella typhi
US5468485A (en) * 1987-06-04 1995-11-21 Washington University Avirulent microbes and uses therefor
IL86583A0 (en) * 1987-06-04 1988-11-15 Molecular Eng Ass Vaccine containing a derivative of a microbe and method for the production thereof
DE3853683T2 (en) * 1987-10-07 1995-08-31 Univ Washington METHOD FOR OBTAINING A DESIRED RECOMBINANT GENE IN A GENETIC CELL POPULATION.
ATE183241T1 (en) * 1993-05-17 1999-08-15 Akzo Nobel Nv VACCINE AGAINST STREPTOCOCCUS SUIS INFECTION
DE69417717T2 (en) * 1993-12-20 1999-10-07 Akzo Nobel N.V., Arnheim/Arnhem Vaccine for the protection of horses against equine herpes virus infections

Similar Documents

Publication Publication Date Title
RU97101084A (en) STRAIN STREPTOCOCCUS EQUI, MICROBIOLOGICALLY CLEAN CULTURE, LIVING VACCINE AND METHOD FOR PRODUCING IT
RU94042386A (en) Vaccine against hepatitis containing 3-o-deacylated monophosphoryl-lipid a, use of hepatitis antigen for preparing the preparation for hepatitis treatment, method of hepatitis treatment
HUP9903169A3 (en) Low pathogenicity prrs live virus vaccines and methods of preparation thereof
CA2081356A1 (en) Derivatives and analogues of 2-deoxy-2,3-didehydro-n- acetyl neuraminic acid and their use as antiviral agents
CA2134835A1 (en) Live in ovo vaccine
CA2197683A1 (en) Method for preparing an influenza virus, antigens obtained and applications thereof
CA2168583A1 (en) Peptides for inducing cytotoxic t lymphocyte responses to hepatitis b virus
Aleksic et al. Microbiology and epidemiology of yersinioses.
CA2066661A1 (en) Viral vaccine conjugates
HUT46858A (en) Process for producing vaccine against coronavirus of dogs
EP1375511A3 (en) Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus
CA2144317A1 (en) Hepatitis a virus vaccines
CA2115927A1 (en) Peptides for inducing cytotoxic t-lymphocyte responses to hepatitis b virus
WO1997005899A3 (en) Novel vaccines and pharmaceutical compositions using membrane vesicles of microorganisms, and methods for preparing same
CA2243730A1 (en) Streptococcus equi vaccine
MY126520A (en) A reinforced immunogen for an inactivated vaccine against infectious disease caused by the group of japanese encephalitis virus and a method for producing the same
RU93053037A (en) VACCINE AGAINST THE DISEASE OF THE BIRDS BAG AND TREATMENT METHODS
CA2015828A1 (en) Canine corona virus vaccine
CA2181862A1 (en) Mild newcastle disease virus vaccine
ATE132374T1 (en) PREVENTION AND TREATMENT OF RETROVIRAL DISEASE
ZA908189B (en) Infectious bronchitis virus vaccine
HUT52703A (en) Process for producing living vaccines of newcastle disease virus
FI953371L (en) Improved vaccines for immunization against TBE virus infection and method for their preparation
CA2087003A1 (en) Hrsv vaccine
HUP9700975A2 (en) Live attenuated rtx-producing bacteria of the family pasteurellaceae